Mr. Robert Andrade reports

FENNEC PHARMACEUTICALS TO REPORT FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS ON MARCH 21, 2024

Fennec Pharmaceuticals Inc. will release its full year and fourth quarter 2023 financial results before the opening of the United States financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the company's financial and business results.

Conference call and webcast details

Date:  Thursday, March 21, 2024

Time:  8:30 a.m. Eastern Time

Webcast:  access on-line

To access the conference call, please register on-line. Upon registration, a dial-in number and unique PIN (personal identification number) will be provided to join the call. To access the live webcast, log onto the company's website and proceed to the news and events/event calendar page under the investors and media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on the company's website for 30 days.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of Pedmark and Pedmarqsi to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, Pedmark received FDA (Food and Drug Administration) approval in September, 2022, and European Commission marketing authorization in June, 2023, for Pedmarqsi. Pedmark has received orphan drug exclusivity in the United States for seven years of market protection and Pedmarqsi has received pediatric-use marketing authorization in Europe, which includes eight years plus two years of data and market protection.